Clinical Trial Update: A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP [Phase 1]

View source ↗

Summary

KINE-101 has completed its first-in-patient Phase 1 trial in patients with corticosteroid-refractory chronic inflammatory demyelinating polyneuropathy (CIDP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Demyelinating Polyneuropathies

Drugs mentioned

• KINE-101

Snippet

Sponsor: Kine Sciences Co., Ltd. | Conditions: CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | Phase 1 | Status: COMPLETED